Company intelligence / Profile preview

Alaxia

Lyon, Auvergne-Rhône-Alpes / Rhone Alpes, Franceorpha.net ↗
Ownership
Private
Employees
~50
Development stage
Phase 1
01

Overview

ALX‑009, Alaxia’s lead compound, has completed or nearly completed Phase I trials in cystic fibrosis and bronchiectasis. It demonstrated promising antimicrobial activity against multi-resistant Gram-negative bacteria. The company also explored its potential virucidal effect against SARS-CoV‑2 in collaboration with academic partners. Patient enrollment for Phase IIa was planned but no published results from later phases are available as of May 2025.

Therapeutic areas
PulmonologyInfectious Diseases
Modalities
Small moleculesAntimicrobial agents
Industry
Biotech
02

Drug pipeline

2 assets

ALX-009

1

1 more asset in the full pipeline.

Request access →
03

Partnerships

iABC consortium under the ND4BB program within IMI (Innovative Medicines Initiative), a public-private partnership between EU & pharma industryUniversity of Padova Department of Molecular Medicine, BSL3 lab collaboration on SARS-CoV‑2 researchSupported by French public bank Bpifrance & Cystic Fibrosis Foundation

Beyond the preview

Go deeper on Alaxia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alaxia.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call